Focused On-demand Library for Programmed cell death protein 2

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

The specialised, focused library is developed on demand with the most recent virtual screening and parameter assessment technology, guided by the Receptor.AI drug discovery platform. This approach exceeds the capabilities of traditional methods and offers compounds with higher activity, selectivity, and safety.

Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by our partner Reaxense.

The library includes a list of the most effective modulators, each annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Furthermore, each compound is shown with its optimal docking poses, affinity scores, and activity scores, offering a detailed summary.

Our top-notch dedicated system is used to design specialised libraries.

Fig. 1. The sreening workflow of Receptor.AI

Our methodology employs molecular simulations to explore a wide array of proteins, capturing their dynamic states both individually and within complexes. Through ensemble virtual screening, we address conformational mobility, uncovering binding sites within functional regions and remote allosteric locations. This thorough exploration ensures no potential mechanism of action is overlooked, aiming to discover novel therapeutic targets and lead compounds across an extensive spectrum of biological functions.

Key features that set our library apart include:

The Receptor.AI platform integrates extensive information about the target protein, such as historical experiments, academic research, known ligands, and structural insights, thereby increasing the likelihood of identifying highly relevant compounds.
The platform’s sophisticated molecular simulations are designed to discover potential binding sites, ensuring that our focused library is optimal for the discovery of allosteric inhibitors and binders for cryptic pockets.
With over 50 customisable AI models, verified through extensive testing in commercial drug discovery and research, Receptor.AI is efficient, reliable, and precise. These models are essential in the production of our focused libraries.
Receptor.AI not only produces focused libraries but also provides full services and solutions at every stage of preclinical drug discovery, with a success-based pricing structure that aligns our interests with the success of your project.

partner

Reaxense

upacc

Q16342

UPID:

PDCD2_HUMAN

Alternative names:

Zinc finger MYND domain-containing protein 7; Zinc finger protein Rp-8

Alternative UPACC:

Q16342; E9PCU7; F5GYS7; Q58HM9; Q58HN0; Q9UH12

Background:

Programmed cell death protein 2, also known as Zinc finger MYND domain-containing protein 7 or Zinc finger protein Rp-8, is speculated to be a DNA-binding protein that plays a crucial role in cellular processes. Its potential regulatory function suggests it may be pivotal in cell death and proliferation, highlighting its importance in maintaining cellular homeostasis.

Therapeutic significance:

Understanding the role of Programmed cell death protein 2 could open doors to potential therapeutic strategies. Its involvement in key cellular functions such as cell death and proliferation makes it a promising target for drug discovery efforts aimed at treating diseases where these processes are dysregulated.